Explore multiplex and single-plex assays across discovery, translation, and clinical research.
Alamar solutions span the continuum from biomarker discovery to screening applications
Comprehensive analysis of health and disease
High sensitivity measurement of validated biomarkers
The NULISA™ DBS Extraction Kit provides a standardized, high-throughput workflow for recovering protein analytes from dried blood and dried plasma spots. Combined with NULISA’s attomolar sensitivity, the kit unlocks high-quality multiplexed proteomic data from minimally invasive, remotely collected samples.
The NULISAqpcr™ Custom Assay Development Kit provides researchers with a flexible solution for creating targeted biomarker assays with high sensitivity and precision. Ideal for applications requiring highly specific and reproducible data, this customizable kit allows scientists to use their own antibodies to create assays tailored to their individual research.
The ARGO HT System, a fully automated, high throughput precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, diagnostics
Alamar’s Technology Access Program provides researchers the opportunity to experience the ultra-high sensitivity of both NULISA™ multiplex and single-plex assays before purchasing the ARGO™ HT System.
CSO
Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.
CFO
Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.
